News & Views
Collaboration yields humanised anti-CD146 antibody
Mar 30 2013
MRC Technology, a technology transfer organisation, has successfully humanised an anti-CD146 monoclonal antibody. The project forms part of an on-going collaboration between MRC Technology and the Institute of Biophysics, Chinese Academy of Sciences (IBP CAS) to develop the antibody as a cancer therapeutic.
The cell adhesion molecule CD146 plays a critical role in tumour angiogenesis, an essential process for cancer development and metastasis. Researchers in the lab of Prof Xiyun Yan at IBP CAS developed an anti-CD146 monoclonal antibody that dramatically inhibits tumour angiogenesis, migration and invasion. Humanisation of the antibody is an essential step in the development of anti-CD146 as a therapeutic.
Dave Tapolczay, MRC Techology’s CEO said: “The IBP CAS is one of the world’s leading academic research institutions and we are very pleased with the results of this collaboration. We are hopeful that the positive evaluation results for the humanised antibody will prove to be a significant milestone in cancer therapy and the fight against the disease.”
MRC Technology has humanised over 50 antibodies to date, including two marketed products, Tysabri (natalizumab) and Actemra (tocilizumab). A further six are in clinical trials (including vedolizumab) and two more in preclinical studies.
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia